Table 3.

PFS in patients with iCCA

Variable	FGFR2 fusions (n = 15)	No FGFR2 alterations (n = 115)	All patients with iCCA (n = 132)a
PFS since start of 1L therapy
Evaluable, n	15	107	124
Overall, median (95% CI), months	6.2 (2.0–16.8)	7.2 (5.0–8.3)	7.1 (5.0–8.3)
Evaluable, n	12	78	91
Platinum-based, median (95% CI), months	4.0 (1.9–NE)	7.1 (4.9–8.2)	6.7 (4.6–8.2)
Evaluable, n	3	21	24
Non-platinum-based, median (95% CI), months	6.2 (3.2–NE)	5.3 (3.0–11.2)	5.3 (3.2–11.2)
PFS since start of 2L therapy
Evaluable	8	81	90
Median (95% CI), months	5.6 (2.8–10.3)	3.7 (2.6–5.6)	3.7 (2.8–5.6)

1L first-line, 2L second-line, CI confidence interval, FGFR2 fibroblast growth factor receptor 2, iCCA intrahepatic cholangiocarcinoma, NE not estimable, PFS progression-free survival

^aTwo patients with other FGFR2 alterations are not presented